Table 4.
The association between steroid and IVIG therapy activation time and neurological sequelae of ANE.
| Therapy | Time | Neurological Sequelae | R | P-value | ||
|---|---|---|---|---|---|---|
| Mild (n = 8) | Moderate (n = 12) | Severe (n = 14) | ||||
| Steroid | ≤24 h | 1 (12.5%) | 1 (8.3%) | 3 (21.4%) | −0.127a | 0.176 |
| >24 h | 7 (87.5%) | 11 (91.7%) | 11 (78.6%) | |||
| ≤72 h | 5 (62.5%) | 6 (50%) | 5 (35.7%) | 0.212a | 0.166 | |
| >72 h | 3 (37.5%) | 6 (50%) | 9 (64.3%) | |||
| IVIG | No | 1 (12.5%) | 1 (8.3%) | 1 (7.1%) | 0.111a | 0.171 |
| ≤24 h | 4 (50%) | 6 (50%) | 6 (42.9%) | |||
| >24 h | 3 (37.5%) | 5 (41.7%) | 7 (50%) | |||
| No | 1 (12.5%) | 1 (8.3%) | 1 (7.1%) | −0.023a | 0.190 | |
| ≤72 h | 5 (62.5%) | 10 (83.3%) | 11 (78.6%) | |||
| >72 h | 2 (25%) | 1 (8.3%) | 2 (14.3%) | |||
a
Use Spearman correlation test.